AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib
This article was originally published in Scrip
Executive Summary
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.